265309-82-8

Usage

Uses

Used in Organic Synthesis:
(2R)-2-[tert-butyl(dimethyl)silyl]oxypropan-1-ol is used as a protecting group for alcohols in organic synthesis. Its silyl-protected hydroxyl group allows for selective reactions on other functional groups, making it a valuable tool in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
(2R)-2-[tert-butyl(dimethyl)silyl]oxypropan-1-ol may have applications in the pharmaceutical industry for the synthesis of specific organic molecules. Its ability to protect hydroxyl groups during selective reactions can be useful in the development of new drugs and pharmaceutical compounds.
Used in Agrochemical Industry:
(2R)-2-[tert-butyl(dimethyl)silyl]oxypropan-1-ol may also have applications in the agrochemical industry for the synthesis of specific organic molecules. Its use as a protecting group for hydroxyl groups can be beneficial in the development of new agrochemicals and pesticides.

Upstream product

• 171230-81-2 (R)-2-(tert-butyl-dimethyl-silanyloxy)-propionic acid methyl ester 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 301346-29-2 (2R)-2-(tert-butyldimethylsilyloxy)-1-(4-methoxybenzyloxy)propane 

Relevant academic research and scientific papers

CYCLIC COMPOUNDS AND METHODS OF USING SAME

The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof which are MALT1 inhibitors. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.

HYDROXAMATE COMPOUNDS AS ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR

The present invention relates to compounds of formula I shown below: (I) wherein R1, R2 and R3 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a receptor activity is implicated, such as, for example, cancer.

TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE

The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.

SUBSTITUTED PYRIDINONE COMPOUNDS AS MEK INHIBITORS

The invention provides novel substituted heterocyclic compounds represented by Formula I and Formula II, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans.

First total synthesis of Aspinolide B, a new pentaketide produced by Aspergillus ochraceus

The first asymmetric total synthesis of Aspinolide B (1), a new 10-membered lactone discovered by chemical screening methods in the cultures of Aspergillus ochraceus, has been accomplished. The key steps included a selective Felkin-type addition of TMS-acetylene to aldehyde 3a and a Nozaki-Hiyama-Kishi coupling reaction to build the required 10-membered ring. This synthesis confirmed the absolute stereochemistry of aspinolide B, established through Helmchen's method and corrected its previously reported specific optical rotation.